Effect of Mifepristone in the Treatment of Uterine Leiomyoma

Abstract

To study the effect of mifepristone in the treatment of uterine leiomyoma. Methods :80 cases of uterine leiomyoma treated in our hospital from August 2019 to August 2020, All patients were treated with mifepristone, It was divided into two groups by random number table, Study group A given low dose (12.50 mg/d), Study group B high dose (25.00 mg/d), The changes of serum hormone levels (follicle stimulating hormone (FSH), luteinizing hormone (LH), progestin (P), estrogen (E2)) and uterine leiomyoma volume were compared between the two groups, The adverse reactions of the two groups were compared. Results: Before treatment, Comparison of FSH、LH、P、E2 level and uterine leiomyoma volume between the two groups, and the difference was not statistically significant (P>0.05). After three months of continuous treatment, FSH、LH、P、E2 level, uterine leiomyoma volume was lower than before treatment, The FSH、LH、P、E2 level of the A group was lower than that of the B group, difference was statistically significant (P<0.05); After three months of continuous treatment, The volume of hysteromyoma in the A group compared with the B group, (b) The difference was not statistically significant (P>0.05); The incidence of adverse reactions in the A group was lower than that in the B group, difference was statistically significant (P<0.05). Conclusion: Patients with uterine leiomyoma are treated with drugs, Low-dose mifepristone can reduce serum hormone levels, promote uterine leiomyoma volume reduction, reduce adverse drug reactions, The application value is remarkable.